Baseball fans, get ready for a surprising move that could shake up the league! The Pittsburgh Pirates have just inked a $1.5 million, one-year deal with pitcher José Urquidy, a seasoned right-hander who’s no stranger to the big leagues. But here’s where it gets intriguing: Urquidy, a 30-year-old veteran, is coming off Tommy John surgery and a brief stint with the Detroit Tigers last season. So, what’s the Pirates’ play here? Let’s break it down.
On Thursday, a source close to the negotiations confirmed the agreement to The Associated Press, speaking anonymously as the deal hinges on Urquidy passing a physical. This move adds depth to a Pirates rotation already boasting NL Cy Young Award winner Paul Skenes. But here’s the twist: Urquidy can be optioned to the minors, giving the Pirates flexibility—a strategic edge that could pay off big time. Or could it backfire? That’s the million-dollar question.
Urquidy’s journey to Pittsburgh hasn’t been without hurdles. After undergoing surgery on June 5, 2024, while with the Houston Astros, he signed a $1 million deal with the Tigers last March. His return to the majors on September 14 was short-lived, with just two relief appearances and a 7.71 ERA over 2 1/3 innings. Is this a risky gamble for the Pirates, or a savvy pickup?
With a career record of 27-16 and a 4.00 ERA over 70 starts and 11 relief appearances for the Astros (2019-23) and Tigers, Urquidy brings experience to the table. He’s also no stranger to high-pressure situations, boasting a 4.08 ERA in 15 postseason appearances, including eight starts. But can he bounce back from injury and deliver for the Pirates? And this is the part most people miss: his minor league optionability could make him a secret weapon—or a costly benchwarmer.
As the Pirates gear up for the season, this move raises more questions than answers. Is Urquidy the missing piece in their rotation puzzle, or a temporary band-aid? What do you think? Is this a smart move by the Pirates, or are they setting themselves up for disappointment? Let us know in the comments—this is one debate you won’t want to miss!
